通年性鼻アレルギ-に対する抗ヒスタミン剤Mequitazine(LM209)の臨床効果--フマル酸クレマスチンとの二重盲検群間比較試験

概要

論文の詳細を見る
The usefulness of LM-209 on perennial nasal allergy was compared with that of clemastine fumarate (CF) at 15 institutions using the double-blind. 28 of them either were excluded or dropped out. The number of patients used for analysing effectiveness, safety and utility were 157, 174 and 160, respectively.The following results were obtained.1) The rate of effectiveness (excellent and good) of LM-209 and CF as judged by doctors was 57% and 51.3%, respectively. The utility rate (excellent utility and utility) of LM-209 was 52.5%, while that of CF was 47.5%.2) The rate of effectiveness (excellent and good) of LM-209 and CF as judged by patients was 34.2% and 30.8%, respectively.3) As far as the patients who had been sick for less than three years and whose time of disease attack did not fluctuate were concerned, the rate of effectiveness of LM-209 was superior to that of CF.4) The rate of side-effects of LM-209 and CF were 14.0% and 21.6%, respectively, especially the rate of drowsiness for LM-209 was significantly lower in comparison with that of CF.5) Abnormal values attributable to the drugs used were observed in a few patients, but administration of drugs was not discontinued in any patient.